RBC Capital Reiterates Outperform on Mirum Pharmaceuticals, Maintains $155 Price Target
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsReiterationPrice Target
RBC Capital analyst Luca Issi reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and maintains $155 price target.
RBC Capital analyst Luca Issi reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and maintains $155 price target.